Bilirubin
[Bilirubin ]
EPTIS Ringversuch Nr. 142480 | Letze Änderung 2024-05-22 | URL: https://www.eptis.bam.de/pts142480 https://www.eptis.bam.de/pts142480
Name des Anbieters | ||||||||||
Name des Anbieters | Weqas Weqas | |||||||||
Ansässig in | United Kingdom | |||||||||
Sprache(n) | ||||||||||
Anmerkungen | In adults, Total Bilirubin is typically measured for the investigation of jaundice as part of a panel of ‘liver function’ tests. Conjugated hyperbilirubinemia is indicative of hepatobiliary dysfunction and bilirubin is often used to monitor the course of the disease. An elevated serum unconjugated bilirubin is characteristic of haemolytic conditions or where there is ineffective erythropoiesis, however total bilirubin very rarely exceeds 100 μmol/L in such conditions. The Bilirubin EQA programme is designed to assess laboratory and method performance in the laboratory investigation of jaundice for adults and neonates. Four liquid human serum samples are distributed monthly, with a minimum of 48 samples distributed over the year covering the clinically relevant range. The samples consist of a panel of 8 linearly related samples produced from donations from healthy volunteers spiked with conjugated and a mixed isomer source of unconjugated bilirubin. The four samples per distribution allows for the assessment of within laboratory imprecision whilst distribution of the same sample on a number of occasions over the year allows for the assessment of between batch imprecision. This programme is designed to assess laboratory and method performance, including linearity, bias, within and between batch imprecision. Key Features: - Liquid human serum samples. Panel of samples covering the pathological range for the laboratory assessment of jaundice in neonates and adults. - Programme design assesses both laboratory and method performance, including linearity, bias, within and between batch imprecision. - Suitable for Laboratory analysers, Blood Gas analysers and POCT devices. - Scoring based on Milan Model 3 performance specification. For more information: https://www.weqas.com/services/eqa/bilirubin/ or contact@weqas.com | |||||||||
Klassifizierung | ||||||||||
Produktgruppen |
Health care / medical devices
|
|||||||||
Prüfgebiete |
Medical analysis
|
|||||||||
Technische Einzelheiten | ||||||||||
|
||||||||||
Ringversuchsziele | ||||||||||
Zielgruppe des Ringversuchs | Suitable for Laboratory analysers, Blood Gas analysers and POCT devices. | |||||||||
Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | |||||||||
Weitere Ziele | validation of testing methods | |||||||||
Teilnehmerzahl | ||||||||||
Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
|||||||||
Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||
Kosten | ||||||||||
Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||
Regelmässig durchgeführt | Ja (Frequency: Monthly. Samples: 4 x 1.0mL. ) | |||||||||
Der Ringversuch wird durchgeführt seit | 1968 | |||||||||
Kontaktdaten des Anbieters | ||||||||||
Anbieter | Kontaktperson | |||||||||
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |